Financials

News Discussions Technicals Forecast Seasonals

0RAG fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to ABIONYX PHARMA EUR0.05 operating, investing, and financing activities

0RAG free cash flow for H1 24 is -1.9 M EUR. For 2023, 0RAG free cash flow was -3.8 M EUR and operating cash flow was -3.7 M EUR.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—